TLD-1(新型脂质体多柔比星)在晚期实体瘤患者中的剂量递增与扩展部分:多中心开放标签Ⅰ期试验(SAKK 65/16)
这项多中心开放标签Ⅰ期首次人体试验纳入30例标准治疗失败的晚期实体瘤患者,TLD-1每3周静脉给药,起始剂量10 mg/m2,采用加速滴定后改良持续再评估法。未观察到剂量限制性毒性,最大给药剂量45 mg/m2,推荐的Ⅱ期剂量为40 mg/m2;最常见治疗相关不良事件为手足红斑感觉异常综合征(50%)和口腔黏膜炎(50%),总体客观缓解率10%,乳腺癌患者中为23.1%。
要点
- TLD-1每3周静脉给药,最大给药剂量45 mg/m2,推荐的Ⅱ期剂量为40 mg/m2。
- 未观察到剂量限制性毒性;最常见任何级别治疗相关不良事件为手足红斑感觉异常综合征(50%)和口腔黏膜炎(50%)。
- 总体客观缓解率10%,13例乳腺癌患者中客观缓解率23.1%,中位治疗失败时间2.7个月。
核心结论
- 新型脂质体多柔比星TLD-1显示出良好的安全性特征和抗肿瘤活性,尤其在乳腺癌中;推荐的Ⅱ期剂量为40 mg/m2,每3周给药一次。
研究设计与样本
- 多中心开放标签Ⅰ期首次人体试验(SAKK 65/16),包含剂量递增和扩展部分。
- 纳入标准治疗失败且接受过最多3线姑息性全身化疗的晚期实体瘤患者。
- TLD-1每3周静脉给药,最多9个周期(既往使用过蒽环类药物的患者为6个周期),起始剂量10 mg/m2,采用加速滴定设计后改良持续再评估法。
- 2018年11月至2021年5月共入组30例患者。
主要发现
- 未观察到剂量限制性毒性;最大给药剂量为45 mg/m2,推荐的Ⅱ期剂量定义为40 mg/m2。
- 任何级别最常见治疗相关不良事件包括手足红斑感觉异常综合征(50%的患者)、口腔黏膜炎(50%)、乏力(30%)和皮疹(26.7%)。
- 最常见的3级治疗相关不良事件为手足红斑感觉异常综合征4例(13.3%)和口腔黏膜炎2例(6.7%)。
- 全人群总体客观缓解率为10%,13例乳腺癌患者中客观缓解率为23.1%;中位治疗失败时间为2.7个月。
- TLD-1显示线性药代动力学,中位终末半衰期为95小时。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional doxorubicin liposomal formulations in preclinical models. This phase I first-in-human study aimed to define the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety and preliminary activity of TLD-1 in patients with advanced solid tumors. PATIENTS AND METHODS: We recruited patients with advanced solid tumors who failed standard therapy and received up to 3 prior lines of palliative systemic chemotherapy. TLD-1 was administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) from a starting dose of 10 mg/m2, according to an accelerated titration design followed by a modified continual reassessment method. RESULTS: 30 patients were enrolled between November 2018 and May 2021. No dose-limiting toxicities (DLT) were observed. Maximum administered dose of TLD-1 was 45 mg/m2, RP2D was defined at 40 mg/m2. Most frequent treatment-related adverse events (TRAE) of any grade included palmar-plantar erythrodysesthesia (PPE) (50% of patients), oral mucositis (50%), fatigue (30%) and skin rash (26.7%). Most common G3 TRAE included PPE in 4 patients (13.3%) and oral mucositis in 2 (6.7%). Overall objective response rate was 10% in the whole population and 23.1% among 13 patients with breast cancer; median time-to-treatment failure was 2.7 months. TLD-1 exhibit linear pharmacokinetics, with a median terminal half-life of 95 h. CONCLUSIONS: The new liposomal doxorubicin formulation TLD-1 showed a favourable safety profile and antitumor activity, particularly in breast cancer. RP2D was defined at 40 mg/m2 administered every 3 weeks. (NCT03387917).
引用
- Colombo I, Koster KL, Holer L, et al. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer. 2024. PMID: 38377773. doi:10.1016/j.ejca.2024.113588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。